CLINICAL TRIALS PROFILE FOR HYTRIN
✉ Email this page to a colleague
All Clinical Trials for HYTRIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00449683 ↗ | Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin | Completed | National Alliance for Research on Schizophrenia and Depression | Phase 4 | 2007-03-01 | The study consists of measurement of antidepressant-induced excessive sweating and its treatment with an experimental medication, terazosin (approved for hypertension), that will be added to the antidepressant. This study is for people who take an antidepressant due to a depressive disorder. This is an open-label study (no placebo group) that will last 5 weeks, with one week of baseline measurement and four weeks of treatment with the study medication. The study is based on the hypothesis that terazosin will be effective in reducing the severity of excessive sweating caused by antidepressant treatment, and will have minimal side-effects. |
| NCT00449683 ↗ | Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin | Completed | Thomas Jefferson University | Phase 4 | 2007-03-01 | The study consists of measurement of antidepressant-induced excessive sweating and its treatment with an experimental medication, terazosin (approved for hypertension), that will be added to the antidepressant. This study is for people who take an antidepressant due to a depressive disorder. This is an open-label study (no placebo group) that will last 5 weeks, with one week of baseline measurement and four weeks of treatment with the study medication. The study is based on the hypothesis that terazosin will be effective in reducing the severity of excessive sweating caused by antidepressant treatment, and will have minimal side-effects. |
| NCT02244255 ↗ | FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia | Completed | Boehringer Ingelheim | Phase 4 | 1998-08-01 | 1. To study the early onset of symptomatic relief afforded by FLOMAX® capsules, 0.4 mg daily as compared to HYTRIN® capsules, 5 mg (with titration) daily in patients with the signs and symptoms of benign prostatic hyperplasia (BPH) 2. To evaluate patient's tolerability to the use of FLOMAX® capsules 0.4 mg daily in comparison to HYTRIN® capsules, 5 mg (with titration) daily for the treatment of the symptoms of benign prostatic hyperplasia |
| NCT03905811 ↗ | Terazosin for Parkinson's Disease | Completed | University of Iowa | Phase 1/Phase 2 | 2019-09-24 | The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD. |
| NCT03905811 ↗ | Terazosin for Parkinson's Disease | Completed | University of Iowa Institute of Clinical and Translational Sciences | Phase 1/Phase 2 | 2019-09-24 | The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD. |
| NCT03905811 ↗ | Terazosin for Parkinson's Disease | Completed | Jordan Schultz | Phase 1/Phase 2 | 2019-09-24 | The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HYTRIN
Condition Name
Clinical Trial Locations for HYTRIN
Trials by Country
Clinical Trial Progress for HYTRIN
Clinical Trial Phase
Clinical Trial Sponsors for HYTRIN
Sponsor Name
